The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...

Please provide your email address to receive an email when new articles are posted on . Among adults with type 2 diabetes, biosimilar insulin was noninferior to insulin glargine for lowering HbA1c, ...

Original Medicare (Part A and Part B) does not cover insulin glargine (Basagalar). Medicare Part C and Part D cover some forms of insulin if you have diabetes, but coverage depends on the plan‘s ...

The upward trajectory of insulin prices in the United States seems to be hitting a speed bump, as two of the biggest manufacturers are now pledging to restrain increases and offer discounts to ...

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly ...

INDIANAPOLIS (WISH) — Indianapolis-based Eli Lilly and Company is offering a response following a Monday protest about insulin prices by a diabetes patient advocate group. T1 International is a ...

Drug companies routinely make hidden pacts with middlemen. This is a Kaiser Health News story. Lisa Crook was lucky. She saved $800 last year after her insurance company started covering a new, less ...

Eli Lilly is cutting the price of its insulin products, announcing Wednesday a plan to reduce the cost of its branded drug Humalog and set a $25-per-vial cap on a non-branded Humalog alternative. The ...